P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

Meta-analysis (6 trials;n=24 096) found P2Y12 inhibitor monotherapy linked to similar risk of death, MI, or stroke, with evidence this may be modified by sex & lower bleeding risk vs. dual antiplatelet therapy (primary outcome occurred in 2.94 vs. 3.36%;HR 0.90, 95% CI 0.77-1.08)

Source:

British Medical Journal